Leukemia likely due to deterioration of the samples over years. Results were similar when using a 5 × 10 −3 threshold and lower thresholds can of course be used in the same way, provided that the sensitivity is sufficient.
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TO THE EDITOR
In view of the importance of methotrexate (MTX) therapy in the treatment of childhood ALL particularly during the consolidation and maintenance phases of treatment, identifying parameters associated with MTX sensitivity and resistance have direct relevance to the treatment of patients with ALL. Pharmacologic and biologic parameters which correlate with clinical MTX sensitivity and resistance in the treatment of ALL include: (1) altered intracellular MTX transport via the reduced folate carrier (RFC); (2) generation of long-chain MTXpolyglutamates catalyzed by folypolyglutamate synthase (FPGS); (3) levels of dihydrofolate reductase (DHFR), the primary target of MTX inhibition; and (4) the relationship of MTX sensitivity and leukemia cytogenetics including hyperdiploidy. [1] [2] [3] [4] [5] [6] It is conceivable that additional factors may also be determinants of MTX response.
The main mechanism of action of MTX as an anti-folate agent, results in the depletion of metabolically active pools of tetrahydrofolate cofactors with a suppression of folate-dependent synthesis of DNA, RNA and protein and thus, it is conceivable that alterations in reduced folate pools may lead to altered MTX sensitivity. Recently, polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR) (gene localized to 1p36.3), an enzyme which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the main circulating form of reduce folates, have been identified. Reduced activity of the MTHFR C677T allele (with the resultant substitution of valine for alanine), in both the heterozygous and homozygous state has been linked to hyperhomocysteinemia due to folate pool imbalances. In this pilot study, we determined if there was a relationship between the MTHFR C677T genotype and in vitro MTX sensitivity in pediatric ALL patients. Cryopreserved lymphoblasts were available from six patients with ALL treated at Children's Hospital of Michigan (CHM) who had suffered from MTX-related neurotoxicity (eg seizures) or hepatotoxicity (eg persistent elevation in transaminase levels) and the MTHFR gene status had been analyzed to assess if there was a relationship with MTX toxicity. Increased treatment-related toxicity has been reported in breast cancer patients homozygous for the MTHFR C677T allele treated with combined cyclophosphamide, MTX, fluorouracil therapy and bone marrow transplant patients who received MTX for graft-versus-host disease prophylaxis. 8, 9 MTHFR genotype for the C677T allele was determined by PCR amplification of DNA extracted from peripheral blood lymphocytes obtained from the patients in remission. Following PCR amplification of the MTHFR gene from genomic DNA, the PCR products were digested with the restriction enzyme HinfI with the DNA fragments size separated on a agarose gel. MTX in vitro sensitivity was determined by an in situ thymidylate synthase inhibition assay with (1) short-term 3 h exposure to MTX followed by an 18 h drug-free period and (2) In this group of six ALL patients, the two patients homozygous for the MTHFR C677T allele (T/T), exhibited greater MTX sensitivity compared to patients with the wild-type (C/C) or heterozygous (T/C) genotypes and were classified as high risk by the NCI leukemia classification (Table 1) . Of note, none of the patients studied had cytogenetic evidence of hyperdiploidy, a group which is known to have a favorable response to MTX. One of the two samples with the C/C genotype demonstrated greater MTX sensitivity compared to the samples with the heterozygous (T/C) genotype; this sample may have exhibited other parameters which contribute to MTX sensitivity including increased RFC expression and/or low DHFR levels. These preliminary results suggest that the relationship of MTX sensitivity and 
